Synthesis and Immunological Evaluation of Escherichia coli O1-Derived Oligosaccharide-Protein Conjugates toward Avian Pathogenic Escherichia coli O1 Vaccine Development
K. Toshima and D. Takahashi describe a way to develop an avian pathogenic Escherichia coli O1 vaccine.
Avian Escherichia coli O1 (APEC O1) is a pathogenic bacterium that causes significant economic losses to the poultry industry and is also feared to cause zoonotic infections due to its genomic similarity to human pathogenic E. coli. In addition, the emergence of drug-resistant strains is a concern and the development of a glycoconjugate vaccine with a high safety profile would be strongly desirable. However, the glycan structures of APEC O1 antigen have not been clarified yet, which does not help the development of such a vaccine.
The group of Professor Kazunobu Toshima and Associate Professor Daisuke Takahashi at Keio University (Yokohama, Japan) has been studying this area, focusing on the three glycan structures O1A, O1B, and O1C, reported to be present in E. coli O1. They hypothesized that the O1A antigen structure, which has been reported to be pathogenic, may be important as a potential glycotope for APEC O1.